Compounded Semaglutide Access for New York Providers
New York medical providers ordering compounded semaglutide and tirzepatide face a specific regulatory landscape. Here is what NY clinics need to know about 503A/503B access.
New York is one of the most heavily regulated states for medical practice and pharmacy operations in the country — and that regulatory environment extends to compounded GLP-1 medications. For licensed New York providers looking to offer compounded semaglutide or tirzepatide to their patients, understanding the compliance landscape is essential before placing your first order.
This guide is written specifically for New York-licensed MDs, DOs, NPs, and PAs who are evaluating compounded GLP-1 supply options for their practices.
The New York Regulatory Framework for Compounded GLP-1s
New York's Office of the Professions and the New York State Board of Pharmacy both have jurisdiction over compounding-related activities within the state. However, when it comes to sourcing from out-of-state 503B outsourcing facilities, federal law governs.
503B Outsourcing Facilities — FDA-registered 503B facilities operate under federal oversight and can legally ship compounded GLP-1s to licensed New York providers for office use. This is the primary supply pathway for high-volume New York clinics. The facility does not need a New York state pharmacy license to ship to your practice, provided it holds current FDA registration and cGMP certification.
503A Pharmacies — New York-licensed 503A compounding pharmacies can fill patient-specific prescriptions for compounded semaglutide and tirzepatide. Out-of-state 503A pharmacies shipping into New York must hold a New York non-resident pharmacy license. MedClinic Partners works with pharmacies that hold the appropriate licensure for New York.
New York Prescribing Requirements — New York requires a valid patient-provider relationship for prescribing compounded medications. Telehealth prescribing is permitted in New York, but providers must comply with New York's telehealth regulations, including documentation requirements and prescribing standards.
What New York Providers Are Ordering
New York's clinic landscape is diverse — from Manhattan concierge medicine practices and Brooklyn medical spas to suburban primary care offices and Long Island weight loss clinics. Demand patterns vary accordingly:
Compounded Semaglutide — The dominant GLP-1 in New York. High-volume Manhattan and Brooklyn practices typically prefer lyophilized formulations for shelf stability. Suburban practices often start with liquid formulations and transition to lyophilized as patient volume grows.
Compounded Tirzepatide — Growing rapidly in New York, particularly among concierge and functional medicine practices. Tirzepatide's dual GIP/GLP-1 mechanism delivers stronger weight loss outcomes for many patients, making it a premium offering for New York practices.
Peptide Add-Ons — New York providers frequently pair GLP-1 programs with USA cGMP RUO peptides such as BPC-157 and TB-500 for recovery and inflammation support, or CJC-1295/Ipamorelin for growth hormone optimization.
Compliance Priorities for New York GLP-1 Programs
New York providers running GLP-1 programs should pay particular attention to:
Documentation Standards — New York's Office of the Professions expects thorough patient documentation for compounded medication prescribing. Ensure your EMR captures the clinical rationale for compounded vs. branded GLP-1 use.
Storage Requirements — Compounded GLP-1 injectables require refrigeration at 2–8°C. New York practices must maintain compliant medication storage logs, particularly if subject to DOH inspections.
Shortage Status — Compounded semaglutide and tirzepatide are only legally available when the branded equivalents are on the FDA shortage list. MedClinic Partners monitors shortage status continuously and notifies all clinic partners of changes.
Certificate of Analysis — New York providers should request and retain CoAs for every lot of compounded GLP-1 received. MedClinic Partners provides full lot documentation through the portal.
How MedClinic Partners Serves New York Providers
We supply compounded GLP-1s to licensed medical practices throughout New York — Manhattan, Brooklyn, Queens, the Bronx, Staten Island, Long Island, Westchester, and upstate New York.
Overnight Delivery to New York — All orders ship overnight in temperature-controlled packaging. New York City deliveries typically arrive before noon the following business day.
Same-Day Portal Access — New York providers can apply and receive portal access within 24 hours of NPI verification. No minimum order requirements to start.
Compliance Support — Our team is available to assist New York practices with documentation, CoA requests, and compliance questions related to their GLP-1 programs.
Getting Started as a New York Provider
The application process takes under five minutes. Submit your NPI, New York license information, and practice details through our portal. Verification typically completes within hours, and you'll have access to our full product catalog and wholesale pricing the same day.
New York is one of our most active markets. Whether you're launching a new GLP-1 program or looking for a more reliable supply partner, we're ready to support your practice.
Explore Topics
Written by
Ian J.
Co-Founder & Managing Partner — Mass-Tort Pharma Background & Medical Operator
Ian is a co-founder of MedClinic Partners with over a decade of experience in mass-tort pharmaceutical matters and medical practice operations. He has personally overseen the launch and compliance infrastructure of multiple GLP-1 and peptide programs, and brings a unique legal-operational perspective to compounding supply chain management.
Editorial standards: All content on medclinicpartners.com is reviewed by licensed medical operators and compounding compliance specialists before publication. Articles are updated when regulatory guidance changes. This content is for licensed healthcare providers only and does not constitute medical advice.
